Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc. company was founded in 1986 and is based in Tarrytown, New York. Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company, in collaboration with Wyeth Pharmaceuticals, provides RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation (OIC) in advanced illness patients receiving palliative care. It is also developing the HIV entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the entry co-receptor, CCR5, and is in Phase II clinical testing; and a novel HCV entry inhibitor, PRO 206. In addition, Progenics Pharmaceuticals is conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate (ADC) designed to selectively target prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as in blood vessels supplying non-prostatic solid tumors; and various Phase I clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

Contact Details

Office Address

Progenics Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY, USA 10591
Phone: (914) 789-2800
Fax: (914) 789-2817

Executives

Founder, Chief Exec. Officer, Chief Science Officer and Exec. Director

Dr. Paul J. Maddon

Chief Financial Officer

Mr. Robert A. McKinney

Business Reviews for Progenics Pharmaceuticals, Inc.

Related Companies